CO2020009992A2 - Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación - Google Patents

Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación

Info

Publication number
CO2020009992A2
CO2020009992A2 CONC2020/0009992A CO2020009992A CO2020009992A2 CO 2020009992 A2 CO2020009992 A2 CO 2020009992A2 CO 2020009992 A CO2020009992 A CO 2020009992A CO 2020009992 A2 CO2020009992 A2 CO 2020009992A2
Authority
CO
Colombia
Prior art keywords
bilastine
cyclodextrin
gelling agent
beta
ophthalmic compositions
Prior art date
Application number
CONC2020/0009992A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernández
Poladura Pablo Morán
Gorostiza Ana Gonzalo
Cerdeiras Paloma Tato
Arce Arturo Zazpe
Hernando Nieves Fernández
García Tania González
Espinar Francisco Javier Otero
Ferreiro Anxo Fernández
Tomé Victoria Díaz
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of CO2020009992A2 publication Critical patent/CO2020009992A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica oftálmica acuosa que comprende: a) al menos el 0,4% p/v de bilastina, de fórmula o una sal o solvato farmacéuticamente aceptable de la misma, en la que la bilastina, sal o solvato de la misma se disuelve completamente en la composición farmacéutica; b) al menos una -ciclodextrina; y c) al menos un agente de gelificación soluble en agua farmacéuticamente aceptable; y en la que el pH está comprendido entre 4 y 9, y a su uso en el tratamiento y/o la prevención de estados mediados por receptor de histamina H1, tales como trastornos o enfermedades alérgicos. La invención se refiere al tratamiento y/o prevención de conjuntivitis alérgica.
CONC2020/0009992A 2018-01-18 2020-08-13 Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación CO2020009992A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382021 2018-01-18
PCT/EP2019/050433 WO2019141563A1 (en) 2018-01-18 2019-01-09 Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent

Publications (1)

Publication Number Publication Date
CO2020009992A2 true CO2020009992A2 (es) 2021-01-18

Family

ID=61017875

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0009992A CO2020009992A2 (es) 2018-01-18 2020-08-13 Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación

Country Status (27)

Country Link
US (1) US20210128544A1 (es)
EP (2) EP3740191B1 (es)
JP (1) JP7309729B2 (es)
KR (1) KR20200111727A (es)
CN (1) CN111727035B (es)
AR (1) AR114216A1 (es)
AU (1) AU2019209214B2 (es)
BR (1) BR112020014265A2 (es)
CA (1) CA3088740A1 (es)
CL (1) CL2020001895A1 (es)
CO (1) CO2020009992A2 (es)
CY (1) CY1124270T1 (es)
DK (1) DK3740191T3 (es)
EA (1) EA202091725A1 (es)
ES (1) ES2878107T3 (es)
HR (1) HRP20211037T1 (es)
HU (1) HUE054594T2 (es)
LT (1) LT3740191T (es)
MA (1) MA51612B1 (es)
MX (1) MX2020007692A (es)
PL (1) PL3740191T3 (es)
PT (1) PT3740191T (es)
SA (1) SA520412443B1 (es)
SI (1) SI3740191T1 (es)
TW (1) TWI833727B (es)
UY (1) UY38055A (es)
WO (1) WO2019141563A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023156559A1 (en) 2022-02-17 2023-08-24 Faes Farma, S.A. Bilastine composition for once-daily parenteral administration
CN115970066A (zh) * 2022-12-29 2023-04-18 成都爱睿康乐医疗器械有限公司 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
JP3527256B2 (ja) 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
KR100673140B1 (ko) 2002-04-19 2007-01-22 파에스 파마, 에스.에이. 4-[2-[4-[1-(2-에톡시에틸)-1Ｈ-벤즈이미다졸-2-일] -1-피페리디닐]에틸]- α,α-디메틸- 벤젠아세틱 애시드의 동질이상체
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US7247623B2 (en) * 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
CN101460176B (zh) * 2006-03-31 2012-11-28 维斯塔肯药品有限责任公司 眼变态反应治疗
ES2752823T3 (es) * 2006-03-31 2020-04-06 Vistakon Pharmaceuticals Llc Tratamiento de alergias oculares
PT2173169E (pt) 2007-06-28 2014-09-03 Cydex Pharmaceuticals Inc Entrega nasal de soluções de corticosteróide aquosas
US20100240624A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic Formulations of Ketotifen and Methods of Use
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Also Published As

Publication number Publication date
CY1124270T1 (el) 2022-07-22
CA3088740A1 (en) 2019-07-25
PT3740191T (pt) 2021-07-09
ES2878107T3 (es) 2021-11-18
HRP20211037T1 (hr) 2021-10-01
LT3740191T (lt) 2021-08-10
EP3740191B1 (en) 2021-04-28
EP3915539A1 (en) 2021-12-01
SA520412443B1 (ar) 2022-09-01
TWI833727B (zh) 2024-03-01
BR112020014265A2 (pt) 2020-12-08
MX2020007692A (es) 2020-09-14
UY38055A (es) 2019-08-30
HUE054594T2 (hu) 2021-09-28
TW201932110A (zh) 2019-08-16
CN111727035B (zh) 2024-05-28
WO2019141563A1 (en) 2019-07-25
PL3740191T3 (pl) 2021-11-29
KR20200111727A (ko) 2020-09-29
MA51612B1 (fr) 2021-06-30
EA202091725A1 (ru) 2020-10-12
SI3740191T1 (sl) 2021-09-30
CL2020001895A1 (es) 2020-12-04
CN111727035A (zh) 2020-09-29
MA51612A (fr) 2020-11-25
AU2019209214B2 (en) 2023-11-23
EP3740191A1 (en) 2020-11-25
AR114216A1 (es) 2020-08-05
JP7309729B2 (ja) 2023-07-18
JP2021511317A (ja) 2021-05-06
DK3740191T3 (da) 2021-06-07
US20210128544A1 (en) 2021-05-06
AU2019209214A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
BR112019000849A2 (pt) composições líquidas de limpeza com sistema antibacteriano e método de fabricação das mesmas
BR112019003945A2 (pt) composições oftálmicas
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
EA202190153A1 (ru) Составы ингибитора axl/mer
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CL2023002871A1 (es) Composiciones nasales que comprenden alcaftadina
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
AU2017261303A1 (en) Ophthalmic compositions
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
PE20211978A1 (es) Compuesto heterociclo pentaciclico
MX2020001356A (es) Composiciones farmaceuticas.
PE20091836A1 (es) Formulaciones para el oido para tratar enfermedades y condiciones oticas
AR127431A1 (es) Compuestos novedosos
WO2020065090A3 (en) 5-ht7 antagonist for the treatment of dementia-associated tauopathies